Bronte Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
Bronte Capital Management's REGN Position: Q3 2026 in Review
Bronte Capital Management increased its Regeneron Pharmaceuticals (REGN) stake by 1.5% in Q3 2026, buying an estimated $1.85M and bringing the position to 165,070 shares worth $125M. The position accounts for 12.55% of the portfolio, ranked #1.
Bronte Capital Management first reported a position in REGN in Q4 2020 and has held it in 24 quarters since. The position peaked at $147M in Q2 2024. 1,423 funds tracked by Wall St. Rank hold REGN as of Q3 2026.
- Bronte Capital Management held 165,070 shares of Regeneron Pharmaceuticals worth $125M as of Q3 2026.
- Bronte Capital Management bought 2,452 Regeneron Pharmaceuticals shares in Q3 2026, an estimated $1.85M.
- Regeneron Pharmaceuticals made up 12.55% of Bronte Capital Management's portfolio in Q3 2026, its #1 holding.
- Bronte Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2020 and has held it in 24 quarters since.
- Bronte Capital Management's Regeneron Pharmaceuticals position peaked at $147M in Q2 2024.
- 1,423 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.
Based on Bronte Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.